MX2018012473A - Agentes que reconocen el epitopo de clever-1 y usos de los mismos. - Google Patents
Agentes que reconocen el epitopo de clever-1 y usos de los mismos.Info
- Publication number
- MX2018012473A MX2018012473A MX2018012473A MX2018012473A MX2018012473A MX 2018012473 A MX2018012473 A MX 2018012473A MX 2018012473 A MX2018012473 A MX 2018012473A MX 2018012473 A MX2018012473 A MX 2018012473A MX 2018012473 A MX2018012473 A MX 2018012473A
- Authority
- MX
- Mexico
- Prior art keywords
- epitope
- clever
- binding
- relates
- recognize
- Prior art date
Links
- 101000832225 Homo sapiens Stabilin-1 Proteins 0.000 title abstract 5
- 102100024471 Stabilin-1 Human genes 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102000058040 human STAB1 Human genes 0.000 abstract 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 abstract 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 abstract 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 abstract 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se refiere a un agente y un anticuerpo humanizado o fragmento Fv o Fab de cadena individual capaz de enlazarse a CLEVER-1 que reconoce un epítopo de CLEVER-1, en donde el epítopo es discontinuo y comprende las secuencias: PFTVLVPSVSSFSSR y QEITVTFNQFTK. Esta invención se refiere también a un agente capaz de enlazarse a un epítopo de CLEVER-1 de humano para el uso en remover inmunosupresión inducida por tumor o antígeno. Además, la invención se refiere a una composición farmacéutica que comprende el agente capaz de enlazarse a la CLEVER-1 de humano y un excipiente apropiado.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20165335 | 2016-04-18 | ||
| FI20165336 | 2016-04-18 | ||
| PCT/FI2017/050285 WO2017182705A1 (en) | 2016-04-18 | 2017-04-18 | Humanized anti clever-1 antibodies and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018012473A true MX2018012473A (es) | 2019-06-06 |
| MX390588B MX390588B (es) | 2025-03-20 |
Family
ID=58672610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018012473A MX390588B (es) | 2016-04-18 | 2017-04-18 | Agentes que reconocen el epítopo de clever-1 y usos de los mismos. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11046761B2 (es) |
| EP (2) | EP3445785B1 (es) |
| JP (1) | JP6907229B2 (es) |
| KR (1) | KR102354845B1 (es) |
| CN (1) | CN109311983B (es) |
| AU (1) | AU2017252343B2 (es) |
| BR (1) | BR112018070302A2 (es) |
| DK (1) | DK3445785T3 (es) |
| ES (1) | ES2926511T3 (es) |
| HR (1) | HRP20221149T1 (es) |
| HU (1) | HUE059732T2 (es) |
| LT (1) | LT3445785T (es) |
| MX (1) | MX390588B (es) |
| PL (1) | PL3445785T3 (es) |
| PT (1) | PT3445785T (es) |
| RS (1) | RS63580B1 (es) |
| SI (1) | SI3445785T1 (es) |
| SM (1) | SMT202200360T1 (es) |
| WO (1) | WO2017182705A1 (es) |
| ZA (1) | ZA201806397B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3810195A1 (en) * | 2018-06-21 | 2021-04-28 | Faron Pharmaceuticals OY | Treatment of cancer with clever-1 inhibition in combination with pd-1/pd-l1 inhibitor |
| US20220357348A1 (en) * | 2019-09-24 | 2022-11-10 | Faron Pharmaceuticals Oy | Method for determining potency of therapeutic anti-clever-1 antibody |
| JP7796642B2 (ja) | 2019-11-11 | 2026-01-09 | ファロン ファーマシューティカルズ オサケ ユキチュア | 白血球上での細胞表面マーカーの発現を制御するための抗Ｃｌｅｖｅｒ－１剤、および抗Ｃｌｅｖｅｒ－１に基づくがん治療を導くためのこれらの使用 |
| KR20230005142A (ko) * | 2020-04-20 | 2023-01-09 | 파론 파머수티컬스 오와이 | 인터루킨 억제제와 조합된 clever-1 억제제를 통한 질환의 치료 |
| FI129383B (en) * | 2020-06-15 | 2022-01-31 | Faron Pharmaceuticals Oy | STABLE ANTI-CLEVER-1 ANTIBODY FORMULATION |
| US20230108957A1 (en) * | 2021-10-01 | 2023-04-06 | Regeneron Pharmaceuticals, Inc. | Treatment Of Psychiatric Disorders And Psychiatric Disorder-Associated MRI Phenotypes With Stabilin 1 (STAB1) Inhibitors |
| WO2023105118A1 (en) | 2021-12-07 | 2023-06-15 | Faron Pharmaceuticals Oy | Method for using inflammatory markers to guide anti-clever-1 cancer treatment |
| JP2025516878A (ja) | 2022-05-20 | 2025-05-30 | ファロン ファーマシューティカルズ オサケ ユキチュア | 抗ｃｌｅｖｅｒ－１治療の恩恵を受けるがん患者を同定する方法 |
| WO2023222952A1 (en) | 2022-05-20 | 2023-11-23 | Faron Pharmaceuticals Oy | Method for identifying cancer patients that benefit from anti-clever-1 treatment |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| CA2468888C (en) | 2002-01-09 | 2013-03-12 | Sirpa Jalkanen | Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| WO2006082406A2 (en) | 2005-02-03 | 2006-08-10 | Antitope Limited | Human antibodies and proteins |
| FI20090161A0 (fi) * | 2009-04-22 | 2009-04-22 | Faron Pharmaceuticals Oy | Uusi solu ja siihen pohjautuvia terapeuttisia ja diagnostisia menetelmiä |
| AU2013343556B2 (en) | 2012-11-09 | 2018-06-28 | Transgene Sa | Modulation of monocytes, or precursors thereof, differentiation |
| TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
-
2017
- 2017-04-18 WO PCT/FI2017/050285 patent/WO2017182705A1/en not_active Ceased
- 2017-04-18 HU HUE17722080A patent/HUE059732T2/hu unknown
- 2017-04-18 JP JP2018554536A patent/JP6907229B2/ja active Active
- 2017-04-18 EP EP17722080.3A patent/EP3445785B1/en active Active
- 2017-04-18 PT PT177220803T patent/PT3445785T/pt unknown
- 2017-04-18 US US16/093,257 patent/US11046761B2/en active Active
- 2017-04-18 EP EP22174733.0A patent/EP4124362A1/en not_active Withdrawn
- 2017-04-18 KR KR1020187028563A patent/KR102354845B1/ko active Active
- 2017-04-18 DK DK17722080.3T patent/DK3445785T3/da active
- 2017-04-18 AU AU2017252343A patent/AU2017252343B2/en active Active
- 2017-04-18 MX MX2018012473A patent/MX390588B/es unknown
- 2017-04-18 SM SM20220360T patent/SMT202200360T1/it unknown
- 2017-04-18 LT LTEPPCT/FI2017/050285T patent/LT3445785T/lt unknown
- 2017-04-18 PL PL17722080.3T patent/PL3445785T3/pl unknown
- 2017-04-18 SI SI201731223T patent/SI3445785T1/sl unknown
- 2017-04-18 HR HRP20221149TT patent/HRP20221149T1/hr unknown
- 2017-04-18 ES ES17722080T patent/ES2926511T3/es active Active
- 2017-04-18 BR BR112018070302A patent/BR112018070302A2/pt active Search and Examination
- 2017-04-18 RS RS20220873A patent/RS63580B1/sr unknown
- 2017-04-18 CN CN201780024478.XA patent/CN109311983B/zh active Active
-
2018
- 2018-09-26 ZA ZA2018/06397A patent/ZA201806397B/en unknown
-
2021
- 2021-04-21 US US17/236,684 patent/US12371486B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017252343A1 (en) | 2018-10-11 |
| US20210332128A1 (en) | 2021-10-28 |
| KR20180134876A (ko) | 2018-12-19 |
| CN109311983B (zh) | 2022-05-17 |
| SI3445785T1 (sl) | 2022-11-30 |
| SMT202200360T1 (it) | 2022-11-18 |
| LT3445785T (lt) | 2022-10-10 |
| PT3445785T (pt) | 2022-09-21 |
| ES2926511T3 (es) | 2022-10-26 |
| US20190194317A1 (en) | 2019-06-27 |
| KR102354845B1 (ko) | 2022-01-24 |
| MX390588B (es) | 2025-03-20 |
| EP4124362A1 (en) | 2023-02-01 |
| CN109311983A (zh) | 2019-02-05 |
| PL3445785T3 (pl) | 2022-10-17 |
| WO2017182705A1 (en) | 2017-10-26 |
| HUE059732T2 (hu) | 2022-12-28 |
| CA3020523A1 (en) | 2017-10-26 |
| DK3445785T3 (da) | 2022-09-19 |
| US11046761B2 (en) | 2021-06-29 |
| EP3445785A1 (en) | 2019-02-27 |
| AU2017252343B2 (en) | 2023-10-12 |
| HRP20221149T1 (hr) | 2022-11-25 |
| BR112018070302A2 (pt) | 2019-01-29 |
| JP2019519475A (ja) | 2019-07-11 |
| EP3445785B1 (en) | 2022-06-22 |
| ZA201806397B (en) | 2024-09-25 |
| US12371486B2 (en) | 2025-07-29 |
| JP6907229B2 (ja) | 2021-07-21 |
| RS63580B1 (sr) | 2022-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018012473A (es) | Agentes que reconocen el epitopo de clever-1 y usos de los mismos. | |
| CY1124190T1 (el) | Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση | |
| MX2017002230A (es) | Anticuerpos anti-lag3 y fragmentos de union a antigeno. | |
| PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
| CL2025000403A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| NZ727024A (en) | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau | |
| CO2018000809A2 (es) | Anticuerpos para cd40 | |
| EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
| CU24498B1 (es) | Anticuerpos de factor xi | |
| UY36401A (es) | Conjugados anticuerpos-fármacos | |
| PE20161210A1 (es) | Anticuerpos anti-mcam y metodos de uso asociados | |
| CO2020002060A2 (es) | Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos | |
| PE20161311A1 (es) | Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos. | |
| AR100944A1 (es) | ANTICUERPOS ANTAGONISTAS DE INTERFERÓN a Y w | |
| MX2017007595A (es) | Inmunoterapia para enfermedad angiogenica. | |
| MX2017013333A (es) | Metodo para purificacion de proteina. | |
| AR109683A1 (es) | Anticuerpos contra el factor xi y sus usos | |
| UY37449A (es) | Anticuerpos anti-chikv y usos de éstos | |
| EA201892313A1 (ru) | Гуманизированные антитела против clever-1 и их применение | |
| UY37598A (es) | Anticuerpos miméticos de fgf21 y usos de los mismos | |
| MX2020004074A (es) | Producto de combinacion para el tratamiento de cancer. | |
| MX2018005097A (es) | Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5. | |
| AR107083A1 (es) | Anticuerpos dirigidos a cd32b y métodos de uso de los mismos | |
| ECSP17016757A (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
| EA201692560A1 (ru) | Моноклональные антитела против эпитопа her2 и способы их применения |